AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

50.14USD
23 Apr 2014
Price Change (% chg)

$0.13 (+0.26%)
Prev Close
$50.01
Open
$50.14
Day's High
$50.26
Day's Low
$49.40
Volume
910,230
Avg. Vol
1,680,274
52-wk High
$54.72
52-wk Low
$40.11

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidem... (more)

Overall

Beta: --
Market Cap (Mil.): $79,818.47
Shares Outstanding (Mil.): 1,596.05
Dividend: 0.42
Yield (%): 3.36

Financials

  ABBV.N Industry Sector
P/E (TTM): 19.48 33.12 33.26
EPS (TTM): 2.57 -- --
ROI: 19.40 19.69 18.95
ROE: 105.11 20.39 19.72
Search Stocks

BRIEF-Ablynx initiates phase I study of anti-il-6R nanobody with Abbvie

* Ablynx initiates phase I bioavailability study with subcutaneous formulation of its anti-il-6R nanobody partnered with Abbvie

23 Apr 2014

AbbVie urges U.S. court to avoid gay rights issue in HIV drug case

- An Abbott Laboratories spinoff urged a federal appeals court to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutional protections for gays and lesbians.

19 Apr 2014

AbbVie urges U.S. court to avoid gay rights issue in HIV drug case

April 18 - An Abbott Laboratories spinoff urged a federal appeals court to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutional protections for gays and lesbians.

19 Apr 2014

AbbVie drops legal action in EU drug secrecy case

LONDON - AbbVie, one of the two U.S. companies trying to stop Europe's drugs regulator from releasing previously secret clinical trials data, said on Thursday it had withdrawn lawsuits against the watchdog.

04 Apr 2014

UPDATE 1-AbbVie drops legal action in EU drug secrecy case

* Decision follows EMA acceptance of redactions to documents

04 Apr 2014

AbbVie drops drug secrecy case against EU agency

LONDON, April 3 - AbbVie, one of the two U.S. firms bringing an injunction against Europe's drugs regulator over the issue of trial data secrecy, said on Thursday it had withdrawn its lawsuit.

03 Apr 2014

AbbVie to build manufacturing plant in Singapore

Feb 5 - U.S. drugmaker AbbVie Inc on Wednesday said it will spend $320 million to set up a manufacturing facility in Singapore to produce new drugs for cancer and immunology now in development.

06 Feb 2014

AbbVie sees 2014 approval of hepatitis drugs, shares rise

- AbbVie Inc issued a cautious 2014 profit forecast, but said it expects U.S. approval this year for its potentially lucrative new all-oral treatment for hepatitis C, sending its shares up 3.4 percent.

31 Jan 2014

AbbVie 4th-quarter earnings slide, hit by generics competition

Jan 31 - AbbVie Inc on Friday reported lower fourth-quarter earnings, hurt by generic competition for its medicines, but results matched Wall Street expectations.

31 Jan 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $100.22 +0.04
Pfizer Inc. (PFE.N) $30.92 -0.08
Novartis AG (NOVN.VX) CHF76.25 -0.15
Merck & Co., Inc. (MRK.N) $57.50 -0.27
Roche Holding Ltd. (ROG.VX) CHF256.20 -0.60
Abbott Laboratories (ABT.N) $38.60 0.00
Eli Lilly and Co (LLY.N) $59.56 -0.47

Earnings vs. Estimates

Search Stocks